vemurafenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors | 4185 | 918504-65-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in the BRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenib has anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.92 | g | O |
ADMET properties:
Approvals:
FDA Adverse Event Reporting System (Female)
FDA Adverse Event Reporting System (Male)
FDA Adverse Event Reporting System (Geriatric)
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
Drug Use | Suggest Off label Use Form| |View source of the data|
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None